NBTK.DE vs. ETLI.DE

Last updated Jun 5, 2026

NBTK.DE (Invesco Nasdaq Biotech UCITS ETF) and ETLI.DE (L&G Pharma Breakthrough UCITS ETF) are both Health & Biotech Equities funds - NBTK.DE tracks the Nasdaq Biotechnology while ETLI.DE tracks the Solactive Pharma Breakthrough Value. Both are passively managed. Over the past 5 years, NBTK.DE returned 5.63%/yr vs 2.31%/yr for ETLI.DE. Their correlation of 0.83 suggests significant overlap in exposure. NBTK.DE charges 0.40%/yr vs 0.49%/yr for ETLI.DE.

Performance

NBTK.DE vs. ETLI.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NBTK.DE achieves a 4.27% return, which is significantly higher than ETLI.DE's -0.74% return.

NBTK.DE

• 1D: 2.92%
• 1M: 0.38%
• YTD: 4.27%
• 6M: 3.76%
• 1Y: 39.20%
• 3Y*: 9.94%
• 5Y*: 5.63%
• 10Y*: —

ETLI.DE

• 1D: 2.62%
• 1M: -4.04%
• YTD: -0.74%
• 6M: -2.52%
• 1Y: 22.46%
• 3Y*: 2.83%
• 5Y*: 2.31%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

NBTK.DE vs. ETLI.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
NBTK.DE Invesco Nasdaq Biotech UCITS ETF	4.27%	18.60%	4.57%	2.51%	-6.11%	7.46%	14.59%	17.24%
ETLI.DE L&G Pharma Breakthrough UCITS ETF	-0.74%	22.23%	0.42%	-12.64%	-2.91%	4.98%	15.37%	14.17%

Correlation

The correlation between NBTK.DE and ETLI.DE is 0.85, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.85
Correlation (3Y) Calculated over the trailing 3-year period	0.80
Correlation (5Y) Calculated over the trailing 5-year period	0.81
Correlation (All Time) Calculated using the full available price history since Oct 22, 2019	0.83

The correlation between NBTK.DE and ETLI.DE has been stable across timeframes, ranging from 0.80 to 0.85 - a consistent structural relationship.

Return for Risk

NBTK.DE vs. ETLI.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBTK.DE

NBTK.DE Risk / Return Rank: 71
NBTK.DE Sharpe Ratio Rank: 61
NBTK.DE Sortino Ratio Rank: 63
NBTK.DE Omega Ratio Rank: 56
NBTK.DE Calmar Ratio Rank: 92
NBTK.DE Martin Ratio Rank: 84

ETLI.DE

ETLI.DE Risk / Return Rank: 38
ETLI.DE Sharpe Ratio Rank: 33
ETLI.DE Sortino Ratio Rank: 34
ETLI.DE Omega Ratio Rank: 30
ETLI.DE Calmar Ratio Rank: 49
ETLI.DE Martin Ratio Rank: 44

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NBTK.DE vs. ETLI.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and L&G Pharma Breakthrough UCITS ETF (ETLI.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NBTK.DE	ETLI.DE	Difference
Sharpe ratio: Return per unit of total volatility	2.03	1.16	+0.86
Sortino ratio: Return per unit of downside risk	2.87	1.76	+1.10
Omega ratio: Gain probability vs. loss probability	1.34	1.20	+0.14
Calmar ratio: Return relative to maximum drawdown	6.16	2.40	+3.76
Martin ratio: Return relative to average drawdown	17.06	6.79	+10.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NBTK.DE vs. ETLI.DE - Sharpe Ratio Comparison

The current NBTK.DE Sharpe Ratio is 2.03, which is higher than the ETLI.DE Sharpe Ratio of 1.16. The chart below compares the historical Sharpe Ratios of NBTK.DE and ETLI.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	NBTK.DE	ETLI.DE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.03	1.16	+0.86
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.27	0.13	+0.14
Sharpe Ratio (All Time) Calculated using the full available price history	0.42	0.22	+0.19

Drawdowns

NBTK.DE vs. ETLI.DE - Drawdown Comparison

The maximum NBTK.DE drawdown since its inception was -30.99%, roughly equal to the maximum ETLI.DE drawdown of -30.83%. Use the drawdown chart below to compare losses from any high point for NBTK.DE and ETLI.DE.

Drawdown Indicators

	NBTK.DE	ETLI.DE	Difference
Max Drawdown Largest peak-to-trough decline	-30.99%	-30.83%	-0.16%
Max Drawdown (1Y) Largest decline over 1 year	-6.24%	-9.06%	+2.82%
Max Drawdown (3Y) Largest decline over 3 years	-29.35%	-23.90%	-5.45%
Max Drawdown (5Y) Largest decline over 5 years	-30.99%	-30.83%	-0.16%
Current Drawdown Current decline from peak	-1.44%	-4.86%	+3.42%
Average Drawdown Average peak-to-trough decline	-10.62%	-10.22%	-0.40%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.26%	3.21%	-0.95%

Volatility

NBTK.DE vs. ETLI.DE - Volatility Comparison

The current volatility for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) is 6.41%, while L&G Pharma Breakthrough UCITS ETF (ETLI.DE) has a volatility of 6.89%. This indicates that NBTK.DE experiences smaller price fluctuations and is considered to be less risky than ETLI.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NBTK.DE	ETLI.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.41%	6.89%	-0.48%
Volatility (6M) Calculated over the trailing 6-month period	14.11%	14.09%	+0.02%
Volatility (1Y) Calculated over the trailing 1-year period	19.00%	18.72%	+0.28%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	20.30%	17.22%	+3.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	22.05%	18.91%	+3.14%

NBTK.DE vs. ETLI.DE - Expense Ratio Comparison

NBTK.DE has a 0.40% expense ratio, which is lower than ETLI.DE's 0.49% expense ratio.

Dividends

NBTK.DE vs. ETLI.DE - Dividend Comparison

Neither NBTK.DE nor ETLI.DE has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both NBTK.DE and ETLI.DE in my portfolio?

NBTK.DE and ETLI.DE have a correlation of 0.85, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, NBTK.DE or ETLI.DE?

On fees, NBTK.DE is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, NBTK.DE or ETLI.DE?

NBTK.DE is cheaper with a 0.40% expense ratio, compared with 0.49% for ETLI.DE.

What is the main difference between NBTK.DE and ETLI.DE?

NBTK.DE tracks Nasdaq Biotechnology, while ETLI.DE tracks Solactive Pharma Breakthrough Value. They also come from different issuers: Invesco and Legal & General. Their fees differ too: 0.40% for NBTK.DE and 0.49% for ETLI.DE.